​​​​​© Copyright CONTENT LABORATORY 2025

Marylou has provided contract communications, reputation and brand leadership, as well as content creation, for a range of biopharma and biotech companies. Key engagements include:

Akari Therapeutics – Developed and executed strategic messaging for pipeline asset, including a rare disease clinical program. Partnered with leadership on strategic planning, investor relations, corporate storytelling and scientific/medical narratives. Led communications execution.

Enzyvant (Sumitomo Pharma America) – Partnered with CEO on rare disease regenerative medicine strategy. Led integrated communication strategies spanning regulatory, advocacy, and commercial launch. Directed internal teams and agency resources on brand and communications execution.

Alexion (AstraZeneca Rare Disease) – Spearheaded patient-centered storytelling and culture transformation initiatives to enhance employee engagement. Advised U.S. commercial team on strategic messaging for successful next generation product launch.

Baxalta (now part of Takeda) – Developed global corporate brand strategy and rare disease narrative for IPO and beyond, ensuring seamless brand activation across functions. 

​

Marylou McNally has extensive experience in the healthcare, biopharmaceutical and biotechnology industries, specializing in corporate and commercial communications, corporate reputation and brand management, investor communications, patient support and access communications, advocacy and thought leadership programs. Proven ability to collaborate cross-functionally to develop and execute impactful communications. Passionate about advancing healthcare innovations and supporting access for rare disease patients.

​​​Check out the Magnetic Reputation Content Hub and The Reputation Bank to learn more about our perspective, thinking and writing.